Pisa syndrome in a cohort of Alzheimer's disease patients

Acta Neurologica Scandinavica

Volumn 111, Issue 3, 2005, Pages 199-201

  Vanacore, Nicola ^a   Suzzareddu, G ^b   Maggini, M ^a   Casula, A ^b   Capelli, P ^b   Raschetti, R ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN FRANCESCO HOSPITAL   (Italy)

Author keywords

Aizheimer's disease; Cholinesterase inhibitors; Pisa syndrome

Indexed keywords

BROMAZEPAM; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOTIAZEPAM; DONEPEZIL; RIVASTIGMINE; THIORIDAZINE;

AGED; ALZHEIMER DISEASE; ANAMNESIS; ARTICLE; CASE REPORT; DIARRHEA; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HUMAN; PISA SYNDROME; PLEUROTHOTONUS; POSTMARKETING SURVEILLANCE; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DYSTONIA; FEMALE; HUMANS; INCIDENCE; SYNDROME;

EID: 14044264820     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00388.x     Document Type: Article

References (10)

1. SUZUKI T, MATSUZAKA H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs 2002;16:165-74.
2. STUBNER S, PADBERG F, GROHMANN R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry 2000;61:569-74.
3. MIYAOKA T, SENO H, YAMAMORI C et al. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry 2001;62:573-4.
4. KWAK YT, HAN IW, BAIK J, KOO MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222.
5. VILLAREJO A, CAMACHO A, GARCIA-RAMOS R, et al. Cholinergic-dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol 2003;26:119-21.
6. ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIEDHO LT and The Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
7. ROSLER M, ANAND R, CICIN-SAIN A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-40.
8. WILCOCK GK, LILIENFELD S, GAENS E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000;321:1-7.
9. MCKHAM G, DRACHMAN D, FOLSTEIN M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
10. EKBOM K, LINDHOLM H, LJUNBERG L. New dystonic syndrome associated with butyrophenone therapy. J Neurol 1972;202:94-103.